RTS, S/AS01 vaccine (Mosquirix™): an overview
MB Laurens - Human vaccines & immunotherapeutics, 2020 - Taylor & Francis
Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
Malaria vaccines since 2000: progress, priorities, products
PE Duffy, J Patrick Gorres - npj Vaccines, 2020 - nature.com
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
[HTML][HTML] Safety and efficacy of a monoclonal antibody against malaria in Mali
K Kayentao, A Ongoiba, AC Preston… - … England Journal of …, 2022 - Mass Medical Soc
Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
[HTML][HTML] Key roles of adjuvants in modern vaccines
SG Reed, MT Orr, CB Fox - Nature medicine, 2013 - nature.com
Vaccines containing novel adjuvant formulations are increasingly reaching advanced
development and licensing stages, providing new tools to fill previously unmet clinical …
development and licensing stages, providing new tools to fill previously unmet clinical …
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double …
MS Sissoko, SA Healy, A Katile, F Omaswa… - The Lancet infectious …, 2017 - thelancet.com
Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …
Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised …
Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …
[HTML][HTML] A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants
RTS, S Clinical Trials Partnership - New England Journal of …, 2012 - Mass Medical Soc
Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …
Advances in infectious disease vaccine adjuvants
J Fan, S Jin, L Gilmartin, I Toth, WM Hussein… - Vaccines, 2022 - mdpi.com
Vaccines are one of the most significant medical interventions in the fight against infectious
diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the …
diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the …
Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy
Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …
Advancements in prophylactic and therapeutic nanovaccines
Vaccines activate suitable immune responses to fight against diseases but can possess
limitations such as compromised efficacy and immunogenic responses, poor stability, and …
limitations such as compromised efficacy and immunogenic responses, poor stability, and …